Abstract
Aims
One possible cause of stent thrombosis is an insufficient effect of clopidogrel. In a prospective study, we aimed to optimize the platelet inhibition of clopidogrel low responders (CLR) by multiple electrode platelet aggregometry (MEA)-guided therapy modifications and to evaluate specific major adverse cardiac and cerebrovascular events (MACCE).
Methods and results
ADP-induced platelet aggregation was measured by MEA in 1,005 consecutive patients after stent implantation and 600 mg clopidogrel loading dose. All patients received at least 100 mg aspirin/day. In 118 patients (11.7%), ADP values remained in the reference range generated in 150 controls and were defined as CLR. Significant independent predictors of CLR were acute coronary syndrome (ACS) (OR = 6.54), diabetes (OR = 2.07), use of diuretics (OR = 1.93) or proton pump inhibitors (OR = 1.64) and male gender (OR = 1.83). Ninety-nine CLR were switched to clopidogrel 150 mg/day, leading to an adequate response in 54/99. Subsequently, 44 patients were changed to ticlopidine 2 × 250 mg/day, resulting in an inhibition in 24/44. The remaining 20 patients received 2 × 100 mg cilostazol/day in addition to 75 mg clopidogrel/day. After its recent availability, 19/118 primary CLR were treated with 5–10 mg prasugrel/day. One patient was a prasugrel low responder. The total thienopyridine low response-rate was 2% in our population. The specific MACCE rate (death, non-fatal target vessel myocardial infarction, non-fatal stroke) of the CLR under optimized treatment (except prasugrel) was 2.0% at 30 days and 3.0% during a mean follow-up of 44 weeks.
Conclusion
Clopidogrel low response is present in 1/10 patients and more frequent in ACS-PCI. MEA-guided optimizing of thienopyridine therapy is feasible and results in a very low specific MACCE rate. Low response to all thienopyridines is rare.
Similar content being viewed by others
References
Stettler C, Wandel S, Allemann S et al (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370:937–948
Cook S, Windecker S (2009) Early stent thrombosis: past, present, and future. Circulation 119:657–659
Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al, American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention (2006) ACC/AHA/SCAI 2005 Guideline update for percutaneous coronary intervention-summary article: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 47:216–235
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505–1516
Snoep JD, Hovens MM, Eikenboom JC et al (2007) Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 154:221–231
Sibbing D, Braun S, Morath T et al (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53:849–856
Buonamici P, Marcucci R, Migliorini A et al (2007) Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49:2312–2317
Geisler T, Langer H, Wydymus M et al (2006) Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27:2420–2425
Matetzky S, Shenkman B, Guetta V et al (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171–3175
Geiger J, Teichmann L, Grossmann R, Aktas B, Steigerwald U, Walter U, Schinzel R (2005) Monitoring of clopidogrel action: comparison of methods. Clin Chem 51:957–965
Toth O, Calatzis A, Penz S, Losonczy H, Siess W (2006) Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 96:781–788
Sibbing D, Braun S, Jawanski S et al (2008) Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 99:121–126
Klouche M (2007) Diagnostic methods for platelet function analysis. Transfus Med Hemother 34:20–32
Behr T, Behr W, von Scheidt W (2010) Monitoring of clopidogrel treatment by multiple electrode platelet aggregometry. J Lab Med 34:99–107
Lee BK, Lee SW, Park SW et al (2007) Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol 100:610–614
Wiviott SD, Antman EM, Gibson CM et al, TRITON-TIMI 38 Investigators (2006) Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 152:627–635
Cutlip DE, Windecker S, Mehran R et al, Academic Research Consortium (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351
O’Donoghue M, Wiviott SD (2006) Clopidogrel response variability and future therapies. Clopidogrel: does one size fit all? Circulation 114:e600–e606
Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919–933
Cattaneo M (2010) New P2Y(12) inhibitors. Circulation 121:171–179
Price MJ (2009) Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 119:2625–2632
Price MJ, Berger PB, Teirstein PS et al, GRAVITAS Investigators (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–1105
Althoff T, Fischer M, Langer E, Ziemer S, Baumann G (2009) Reduzierte Thrombozyten-inhibitorische Wirkung von Clopidogrel und ASS im Verlauf nach Stentimplantation bei akutem Myokardinfarkt gegenüber elektiver koronarer Stentimplantation. Clin Res Cardiol 98(Suppl 1), V1678. Abstract
Cuisset T, Frere C, Quilici J et al (2007) High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 97:282–287
Marcucci R, Paniccia R, Antonucci E et al (2007) Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost 98:844–851
Gilard M, Arnaud B, Cornily JC et al (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51:256–260
Siller-Matula JM, Spiel AO, Lang IM et al (2009) Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 157:148 (e1–e5)
Small DS, Farid NA, Payne CD et al (2008) Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 48:475–484
Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301:937–944
Juurlink DN, Gomes T, Ko DT et al (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180:713–718
Stanek EJ (2009) http://www.theheart.org/article/977905.do. Accessed 3 Nov 2009
O’Donoghue ML, Braunwald E, Antman EM et al (2009) Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374:989–997
Sibbing D, Morath T, Stegherr J et al (2009) Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 101:714–719
Rassen JA, Choudhry NK, Avorn J, Schneeweiss S (2009) Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 120:2322–2329
von Beckerath N, Kastrati A, Wieczorek A et al (2007) A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 28:1814–1819
Aleil B, Rochoux G, Monassier JP, Cazenave JP, Gachet C (2007) Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases. J Thromb Haemost 5:879–881
Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA (2000) In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol 49:343–351
Campo G, Valgimigli M, Gemmati D et al (2007) Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol 50:1132–1137
Neubauer H, Lask S, Engelhardt A, Mügge A (2008) How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 99:357–362
Angiolillo DJ, Shoemaker SB, Desai B et al (2007) Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study. Circulation 115:708–716
Mehta SR, Tanguay JF, Eikelboom JW et al, CURRENT-OASIS 7 trial investigators (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376:1233–1243
Wiviott SD, Braunwald E, McCabe C et al, TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015
Acknowledgments
This work was supported by a grant of the Fördergemeinschaft Herzzentrum Augsburg-Schwaben. The results of this study are parts of the MD thesis of T.B., University of Munich, Germany, in preparation.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Behr, T., Kuch, B., Behr, W. et al. Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. Clin Res Cardiol 100, 907–914 (2011). https://doi.org/10.1007/s00392-011-0321-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-011-0321-4